Plain-English translation of NCT06821191 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Coronary Artery Disease research guide →Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
After a stent is placed in a blocked artery, patients typically take two blood-thinning medications together—aspirin and either prasugrel or ticagrelor—to prevent the stent from clotting. This trial tests whether it's safer to reduce the dose of your current medication or to switch to a weaker medication after the riskiest period has passed. The goal is to keep you protected from clots while lowering your risk of serious bleeding.
Most dangerous clots happen in the first few months after a stent, but keeping patients on high-dose blood thinners for a full year increases bleeding risks. This study will help doctors figure out the best way to dial back the medication's strength once the highest-risk period is over.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to either reduce the dose of your current blood-thinning medication or switch to a different, less potent medication. Your doctor will monitor you during follow-up visits to check how well your blood platelets are responding and whether you experience any bleeding or clotting problems. The study involves blood tests to measure how your medication is working.
AI-generated summary from trial data · Aug 6, 2026 · Not medical advice
United States